Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 13 February 2015 | By Alexander Gaffney, RAC,
The House of Representatives’ Energy and Commerce Committee has voted in favor of new legislation that would reform the way in which the US Drug Enforcement Administration (DEA) schedules new drug substances in the hopes of allowing patients to access new therapies more quickly.
The bill in question, the Improving Regulatory Transparency for New Medical Therapies Act, is meant to address a regulatory process some drug companies have described as a "black hole."
While a drug is required to be approved by the US Food and Drug Administration (FDA) in order to be marketed, the DEA must also sign off on drugs subject to the Controlled Substances Act (CSA).
The CSA, which provides for the scheduling of drugs into various classes of control, is meant to ensure that drugs that might be misused or abused aren't as readily available to consumers. For example, a drug subject to Schedule II controls might have restrictions on how many refills are available without a new prescription, and the quantity of product allowed to be prescribed at a single time.
The problem, as Focus has noted, is that DEA can take more than a year to schedule a product under the CSA, even when FDA has made specific recommendations regarding the drugs' scheduling. That delay leaves patients without access to an FDA-approved therapy and companies without the ability to market their drug.
On 12 February 2014, the House Energy and Commerce Committee approved the Improving Regulatory Transparency for New Medical Therapies Act.
The bill, as Regulatory Focus has previously explained, would require DEA to schedule drugs according to a strict timeline, giving drug manufacturers and patients more predictability.
Read our previous coverage of the bill and its provisions here.
The legislation also makes it easier to provide drugs under a clinical trial. DEA would be required to review applications to manufacture a controlled substance (Schedule III, IV or V) for use in a clinical trial within 180 days of receiving the application, and Schedule I or II drugs within 180 days, not including a notice and comment period and a 90-day application window.
The bill now awaits a vote by the full House of Representatives. If passed, the bill would be sent to the Senate, which has previously introduced companion legislation in this area.
Improving Regulatory Transparency for New Medical Therapies Act
Tags: DEA, Drug Enforcement Administration, Improving Regulatory Transparency for New Medical Therapies Act, House, Legislation, Bill
Regulatory Focus newsletters
All the biggest regulatory news and happenings.